VeriPsych is a molecular diagnostic tool designed to complement the healthcare provider’s clinical impression.

VeriPsych, based on the simultaneous measurement of 51 different protein and hormone biomarkers with an associated mathematical decision rule, compares the biomarker profile of a patient with suspected schizophrenia to that of patients with a confirmed diagnosis of schizophrenia.

RBM chief executive officer Craig Benson said that VeriPsych was developed through targeted research combining RBM’s proprietary multiplexing technology and biomarker discovery capabilities, specifically in the area of mental illness.

“VeriPsych is an important step in RBM’s ongoing efforts to develop and provide quantitative diagnostic tools for healthcare providers treating patients with neuropsychiatric disorders,” Benson said.